ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CEL Celadon Pharmaceuticals Plc

92.50
0.00 (0.00%)
Last Updated: 07:39:12
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Celadon Pharmaceuticals Plc LSE:CEL London Ordinary Share GB00BDQYGP38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 92.50 90.00 95.00 92.50 92.50 92.50 13,655 07:39:12
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Investment Advice 24k -17.01M -0.2722 -3.40 57.78M

Appointment of Stockbroker

07/08/2003 10:43am

UK Regulatory


RNS Number:4281O
Celsis International PLC
07 August 2003

The headline for the Celsis International PLC announcement released today at 
7:00 under RNS No: 4201O should read "Appointment of Stockbroker"


The announcement text is unchanged and is reproduced in full below.


                            Celsis International plc

                 Appointment of Seymour Pierce as Stockbroker


Celsis announces the appointment of Seymour Pierce as the Company's stockbroker
with immediate effect.


Seymour Pierce has displayed strong commitment to the Celsis turnaround since
initiating research coverage late last year.  The Seymour Pierce Life Sciences
team, supported by its in-depth research, has sought to actively build
investment interest during a period which has coincided with robust Group
trading and share price performance.


Jay Le Coque, Chief Executive commented:


"We have been impressed with Seymour Pierce's insight, depth of research and
professionalism.  We have also been delighted with their fresh approach in
developing interest amongst institutional investors and look forward to a future
supported by their counsel and support."


Keith Harris, Chairman & Chief Executive, Seymour Pierce commented:


"Our Life Sciences team headed by Dr Brett Pollard has developed a reputation
for offering a hands on service backed by incisive research.


"I am delighted with Celsis' decision to appoint us and we look forward to
working with the board in the coming years."


7 August 2003

Enquiries:

Celsis International plc                                       Tel: 01638 600151
Jay Le Coque, Chief Executive Officer

College Hill                                                  Tel: 020 7457 2020
Nicholas Nelson

Seymour Pierce                                                Tel: 020 7107 8000

Jonathan Wright


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

APPGCGDIBXGGGXR

1 Year Celadon Pharmaceuticals Chart

1 Year Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

1 Month Celadon Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock